52503 The financial burden of scalp cooling therapy: a non-profit organization data analysis
Recommended Citation
Novice M, Novice T, Powers M, Sicco KL. 52503 The financial burden of scalp cooling therapy: a non-profit organization data analysis. J Am Acad Dermatol 2024; 91(3):AB328.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: Scalp cooling therapy (SCT) is currently the most effective method to reduce chemotherapy-induced alopecia (CIA). However, cost (approximately $1500-$3000) can be prohibitive for many patients, and insurance coverage is inconsistent. Non-profit organizations have emerged to help combat this disparity of care by providing need-based funding for SCT. Methods: We reviewed de-identified applicant and financial records from individuals who received SCT funding from a Michigan-based non-profit organization, Cap & Conquer™️(C&C), between September 2020 - April 2023. Results: Of the 112 patients, 82 completed SCT use and 30 discontinued prior to their chemotherapy completion. C&C spent a total of $142,956.65, averaging $1,287.90/patient. Factors that impacted cost included: cap company, percent funding received, chemotherapy length, and SCT outcome (completed vs. discontinued). For the 71 patients (63.4%) who received 100% funding, the average cost per person was $1,454.15. Their average self-reported annual income was $32,953.20 versus $61,339.07 for those who received 75% funding or less. Their average self-reported monthly disposable income was -$91.69 versus $1,089.34 for applicants with 75% or less funding. When considering SCT outcome, the average price per patient who completed SCT was $1,451.39 versus $846.48 in those who discontinued prior to chemotherapy completion. Conclusion: Our data highlights the out-of-pocket cost of SCT. Non-profit funding, while an important resource, is not a sustainable solution. Given long-lasting, psychological implications from CIA in cancer patients, improved insurance coverage is necessary to increase SCT access for all patients.
Volume
91
Issue
3
First Page
AB328
